Raptor Pharmaceutical Corp. (RPTP) : Havens Advisors added new position in Raptor Pharmaceutical Corp. during the most recent quarter end. The investment management firm now holds 110,000 shares of Raptor Pharmaceutical Corp. which is valued at $987,800 , the company said in a statement filed on Oct 13, 2016 with the SEC.Raptor Pharmaceutical Corp. makes up approximately 0.79% of Havens Advisors’s portfolio.
Other Hedge Funds, Including , Legal General Group Plc reduced its stake in RPTP by selling 4,257 shares or 28.46% in the most recent quarter. The Hedge Fund company now holds 10,699 shares of RPTP which is valued at $96,077.Cutler Group Lp reduced its stake in RPTP by selling 34,629 shares or 84.97% in the most recent quarter. The Hedge Fund company now holds 6,126 shares of RPTP which is valued at $55,134.Bnp Paribas Arbitrage Sa boosted its stake in RPTP in the latest quarter, The investment management firm added 2,596 additional shares and now holds a total of 5,953 shares of Raptor Pharmaceutical Corp. which is valued at $53,517.
Raptor Pharmaceutical Corp. closed down -0.02 points or -0.22% at $8.98 with 6,86,578 shares getting traded on Tuesday. Post opening the session at $8.99, the shares hit an intraday low of $8.98 and an intraday high of $9 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Raptor Pharmaceutical Corp. reported $-0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.17. The company had revenue of $32.05 million for the quarter, compared to analysts expectations of $28.51 million. The company’s revenue was up 37.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe PROCYSBI gastro-resistant hard capsules of cysteamine received a marketing authorization from the European Commission (EC) as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine or RP103 and its oral 4-methylpyrazole or Convivia. Its other product Quinsair is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.